Loading patent…
AssigneesThe Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
InventorsDavid Weiner, William Williams, David N. Levy
Estimating the term…
The present invention provides compositions and methods for targeting recombinant retroviral particles specifically to cells of interest for delivery of desired therapeutic or toxic agents. The invention provides chimeric nucleotide constructs, chimeric proteins formed of a selected viral envelope gene from which a selected sequence has been deleted and into which has been inserted all or an effective portion of a heterologous ligand, said ligand or portion thereof capable of binding to a selected receptor, recombinant viral particles formed of the chimeric proteins, a biological mediator for delivery to the target cell; and retroviral gag and pol proteins. The lack of retroviral nucleic acid renders the viral particle replication defective and non-pathogenic.
A chimeric nucleotide construct comprising an HIV gp160 envelope gene from which the sequence encoding about amino acid 392 to about amino acid 446 or a fragment thereof corresponding to the HIV binding site to CD4 has been deleted and into which has been inserted a heterologous sequence encoding a ligand, said ligand selected from the group consisting of GMCSF and CD4.
A chimeric nucleotide construct SEQ ID NO:1.
A chimeric nucleotide construct SEQ ID NO:2.
A vector comprising:
A recombinant retroviral particle comprising:
Dependencies are inferred from the claim text.